Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median…
Encouraging overall response rate of 46% and disease control rate of 98% with a median…
Buyer Registration Link HONG KONG SAR - Media OutReach - 22 October 2023 - Organised…
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of…
XIAMEN, China--(BUSINESS WIRE)--On October 20th, the 24th Conference on The Electric Power Supply Industry kicked…
GURUGRAM, India & NEW YORK--(BUSINESS WIRE)--$MMYT #Fiscal2024--MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal…
Foundation Medicine will transfer FoundationOne®Liquid CDx technology to Sequanta in November 2023 and FoundationOne®CDx technology…
BEIJING, CHINA - Media OutReach - 21 October 2023 - On the evening of October…
Event spotlights next-generation memory solutions for applications such as cloud, edge devices and automotive vehicles…
DUBLIN--(BUSINESS WIRE)--The digital lending scene is undergoing a seismic shift, as highlighted by a recent…
LambdaTest’s Auto-Heal aims to streamline software testing by automatically adapting tests to changes in applications,…